Inovalon’s Post

Why Immunization Against Covid-19 Causes Heart Attack? Angiotensin converting enzyme 2 Angiotensin converting enzyme 2, or ACE2, is an exopeptidase expressed primarily by vascular endothelial cells in the heart and kidneys, but also in respiratory epithelia[1] and in the gastrointestinal tract. It is the target of several coronaviruses, including SARS-CoV and SARS-CoV-2. 2 Biochemistry ACE2 is a transmembrane metallocarboxypeptidase composed of 805 amino acids. Zinc and chloride ions act as cofactors. The extracellular region consists of two domains, a zinc metallopeptidase domain and a C-terminal collectrin homology domain. The enzyme exhibits homology to angiotensin converting enzyme (ACE). ACE2 is encoded by the ACE2 gene on the X chromosome (gene locus Xp22.2). In addition to being expressed as a transmembrane protein, a soluble form exists in serum. 3 Function ACE2 cleaves angiotensin II into angiotensin (1-7), which has anti-inflammatory and lung protective effects via MAS and AT2 receptors. 4 Clinical 4.1 Infectiology ACE2 serves as a major entry point for some coronaviruses. The pathogens bind to the enzyme with their spike proteins and enter the host cell by subsequent fusion.[2] ACE2 expression increases from the pharynx to the alveoli. In addition, SARS-CoV-2 is thought to have a higher affinity for ACE2 than SARS-CoV. This would explain more rapid and effective viral transmission in the COVID-19 pandemic. Patients taking drugs that increase the expression of ACE2 - for example, ACE inhibitors or sartans, may be at higher risk of infection and should be switched to calcium antagonists, according to some authors.[3][4] In contrast, the relevant professional societies see no need for action at this time (4/2020).[5][6] 4.2 Pharmacology Human recombinant ACE2 (APN01) is an experimental therapeutic approach being tested in acute respiratory distress syndrome (ARDS) and pulmonary hypertension.[7] Furthermore, it is currently (2020) being tested for the treatment of COVID-19.[8][9] https://lnkd.in/exKJUk8y

Discover insights from our esteemed keynote speakers at our conferences on February 08-09, 2024, in Madrid, Spain. Don't miss the opportunity to attend their engaging presentations and enhance your knowledge. Join us for an enriching experience! #Conferenceseries #conference2024 #Conference #conferencespeaker #madrid #spain #brain #brainhealth #brainstorming #braininjury #braindisorder #brainresearch #researchanddevelopment #researchers #article #papers #abstractsubmission #abstracts #psychology #vaccines #development

Exciting news in the world of healthcare! Researchers have initiated the trial for the world's first mRNA vaccine targeting the norovirus, a highly contagious virus causing acute gastroenteritis. Developed by Moderna, the mRNA-1403 vaccine aims for a 65% efficacy rate against three major norovirus strains, potentially reducing hospitalizations and global healthcare costs associated with this virus. The phase 3 clinical trial, dubbed Nova 301, will involve 25,000 participants aged 18 and above across 270 locations. The study will explore the vaccine's potential as a seasonal inoculation, akin to the flu shot, or for longer-lasting immunity. With an estimated 685 million people affected and 200,000 deaths annually due to norovirus, this research holds promising implications for public health. For those interested, you can stay updated on the progress of this groundbreaking vaccine trial by following the clinical trials at https://lnkd.in/gZ-UkRV8. Let's keep an eye on this innovative development that could have a significant impact on global health outcomes.

The health industry is only getting better. Here are 5 health & wellness stories from 2023 that you’ve probably missed: 👉New Weight-Loss Drugs Novo Nordisk's Wegovy & Eli Lilly's Mounjaro show potential benefits beyond weight loss, such as reducing heart attack risk and treating addiction. 👉End of COVID Public Health Emergency Policies facilitating access to COVID tests, vaccines, and treatments transitioned to private coverage, marking a shift in the management of the pandemic. 👉Progress in Xenotransplants Surgeons have transplanted a genetically modified pig heart into a human for the 2nd time ever. The recipient only survived for six weeks but this offers hope for addressing organ shortages. 👉The Arrival of RSV Vaccines FDA-approved vaccines protect against respiratory syncytial virus (RSV), offering hope for preventing severe illness in vulnerable populations. 👉Completion of First Face and Eye Transplant Doctors in New York perform the first partial face and whole-eye transplant, providing hope for restoring appearance and function in individuals with traumatic eye injuries. The health and wellness market size worldwide is set to increase to almost 7 trillion U.S. dollars by 2025. This month, we're launching our Healthcare Analytics Course 🇬🇧 and Health & Wellness Product Design course 🇺🇸! What’s been the best medical invention/advancement so far? 👇 Share your thoughts!

From our latest issue: Dr. Madeline King discusses a focus group study that reviewed provider practices to learn more about patient management and explore the potential to follow up with clinicians on important takeaways. #antibiotics

I recently had the pleasure of speaking with DIA about the role of real-world evidence (RWE) in closing health equity gaps and improving outcomes for underserved populations. RWE is a powerful tool that can help us understand the needs, preferences, and experiences of different types of patients in real-world settings. Also, regulators have become more explicit in their requests for diversity data, opening the door for significant improvements in the availability of more representative data to inform regulatory and clinical decisions.    At Johnson & Johnson, we are using RWE to improve representation across different patient populations – such as to inform diversity plans for clinical studies and to facilitate decision-making for special populations, like pregnant and lactating people and children.    And that’s just the beginning. To overcome health equity gaps, innovation that is evidence-based and patient-centered will be key, with RWE playing a crucial role in driving this progress.   I want to thank DIA for the opportunity to bring this important topic to the forefront, and invite you to read the full interview here: https://lnkd.in/efYpyKKJ   #realwordevidence #realworlddata #RWE #healthequity #myCompany #JNJ

The Journal of Allergy and Clinical Immunology, Feb 2024 Olink Proteomics profiling of #nasal fluid #cytokine/chemokine revels how #IL-4Ra blockade (#dupilumab) reduces nasal #polyp burden and upper respiratory symptoms in patients with Aspirin Exacerbated #Respiratory Disease (#AERD). The #Olink data suggest that the #therapeutic benefit of dupilumab in AERD patients is likely mediated by the reduction of the nasal levels of #IL-6 and Oncostatin M (#OSM). Title: "IL-4Rα Blockade Reduces Levels of IL-6 Family Cytokines including Oncostatin M (OSM) and IL-6 in Nasal Fluid of Patients with Aspirin Exacerbated Respiratory Disease (AERD) and Nasal Polyps" IL-4Ra blockade reduces nasal polyp burden and upper respiratory symptoms in patients with AERD. The exact cellular and molecular #mechanisms of therapeutic benefit are unknown. • Olink analysis revealed that there were significantly higher baseline levels of multiple cytokines, particularly the IL-6 family cytokines, OSM and IL-6, in nasal fluid of AERD patients versus controls. • Dupilumab significantly reduced the nasal levels of IL-6 and OSM in AERD patients. • Nasal polyp mast cells and monocytes expressed high levels of OSM transcripts. • IL-4 stimulation of CBMCs and cultured monocytes increased their OSM production, while IL-13 and OSM stimulation of fibroblasts increased their IL-6 production. The dupilumab-induced decrease in nasal OSM and IL-6, which is likely due to direct effects of IL-4Ra blockade on tissue mast cells and monocytes, and both indirect and direct effects on nasal fibroblasts, may be partially responsible for the therapeutic benefit of dupilumab. #biomarkers #omics #Allergy #immunology #pathology #interleukin

I’m excited to share news about our groundbreaking healthcare initiative Voices Collective, powered by People First. Over the past decade, we’ve proudly built the capability to source patients and caregivers by condition, medication, or treatment, all while adhering to the highest standards of compliance. Patient voices have always been vital in healthcare, but today, patients increasingly make decisions based on social searches and community influence. People now turn to their peers rather than the media, government, or corporations for healthcare guidance. Unfortunately, there aren’t enough patients or authentic patient stories to meet the growing demand in marketing and clinical trials. In fact, four out of five clinical trials fail due to insufficient patient recruitment. Marketers are in dire need of compliance-friendly (and non-competitive) solutions. Our team has sourced more than 1,000 patients to date—patients with rare autoimmune disorders, cervical cancers, irritable bowel syndrome, uncommon STIs, and type 2 diabetes, among many others. Our approach tackles diversity, geography, age, and gender beyond the outdated methods of stale databases. We’ve proven that patient stories outperform brand content by 200% in conversion and drive 430% higher recall, because patients seek authenticity and prefer the imperfect. We learned firsthand: • The messenger is as important as the message in healthcare. • Popularity often inversely correlates with persuasion. • Scale is critical. • Patients trust fellow patients. • Healthcare professionals (HCPs) listen to their peers. • Caregivers are proactive and engaged. Our compliance-based platform ingests, enriches, analyzes, and organizes data through AI, a feat unimaginable just a decade ago. We operate with a “humans-in-the-loop” model, given the need for trust when asking patients and HCPs to share their stories on highly personal conditions. Through Voices Collective, powered by People First, brands can now rapidly build bespoke human networks based on specific criteria. Our approach was proven in critical, front-line scenarios. Originally, our purpose was to counter the resurgence of Neo-Nazi and ISIS propaganda online through trusted messengers. I remain deeply grateful to DARPA for providing the initial tools that made this important work possible. We’ve also supported numerous public health campaigns, including the largest-ever peer-to-peer public health initiative for the NIH, CDC, and Ad Council during the COVID-19 vaccine rollout. We’re thankful to the Ad Council for our  Creators for Good partnership, which has helped us source authentic stories for remarkable public health campaigns across various conditions. Given all we’ve accomplished, and the potential ahead, I’d love to set up a time to chat in the coming weeks. I also welcome any introductions within your network to people who may benefit from our services. Best regards, Curtis

The results are in for this epic annual #healthcare conference. The standout for me: #vaccinedevelopment Read on! #jpmorgan #medtech #healthtech #biotech

In Noble Shore's latest blog, he explores how Veridix AI’s technology accelerates vaccine trials with AI-driven solutions, improving timelines and data quality. Read the blog to discover how we're shaping the future of vaccine research.   Noble and our team are attending DPHARM this week at booth # 53, with Noble giving a presentation on how Veridix AI reduces database build time by 60% with AI-driven automation of specs, eCRFs, edit checks, and CDISC datasets.    Visit our booth or see his presentation to learn more.     #AIinClinicalTrials #VaccineResearch #ClinicalInnovation #DPHARM2024 #eClinicalSolutions